NCT02845414

Study of CD133KDEL Toxin in the Treatment for Solid Tumors

Phase I Study Of Stem-Cell Directed Deimmunized CD133KDEL Toxin In The Treatment Of Solid Tumors

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Masonic Cancer Center, University of Minnesota · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single center, phase I dose escalation study designed to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of deimmunized CD133KDEL (dCD133KDEL), a ligand-directed, deimmunized pseudomonas toxin against CD133, in patients with advanced, previously treated, refractory solid tumors.

Conditions

• Solid Tumors

Interventions

Type	Name	Description
DRUG	CD133KDEL (dCD133KDEL)	Patients will receive dCD133KDEL at the assigned dose level via a 30-minute intravenous infusion on days 1, 3, 5, 8, 10 and 12 (total of 6 doses) of a 28-day cycle.

Timeline

• Start date: 2018-12-01
• Primary completion: 2022-01-01
• Completion: 2022-01-01
• First posted: 2016-07-27
• Last updated: 2018-10-03

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study